Silent synapses are dormant neural connections that hold untapped brain potential. Discover how ketamine, exercise, and other ...

The most well-established mechanism for activating silent synapses involves stimulation of NMDA receptors, which triggers a ...

We use cookies and other tracking technologies to improve your browsing experience on our website, to show you personalized content and targeted ads, to analyze our website traffic, and to understand ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx ...

Ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, has emerged as a promising treatment for TRD. Originally an anesthetic, ketamine has shown rapid antidepressant effects ...

Ketamine has long been seen as a potential ... It works on the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor in the brain, and is used alongside a newly prescribed oral ...

Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and full year 2024 earnings call. At this time, all lines are in a listen only mode. Following the presentation, we will ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

The inhaled anesthetics affect many receptors (e.g., GABA A, glycine, acetylcholine, serotonin, NMDA) in manners that plausibly could explain anesthesia. Which receptors mediate anesthesia remains ...

stimulation on NMDA receptor hypofunction by examining the interactive effects of nicotine, a nAChR agonist, and ketamine, a non-competitive NMDA receptor antagonist, on behavioral and ...